HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health, Beauty And Wellness News: Nutrisystem Adds Options, Roar Gains $5.6M, SynTech Elite In US, More News

Executive Summary

Nurtisystem launches FreshStart, South Beach Keto; Roar Beverage $5.6m funding led by AccelFoods; SynTech brings Elite Series to US; ChromaDex extends Tru Niagen to Canada with Fullscript; Nugenix Sexual Vitality Booster with Nitrosigine; Abattis debuts Vergence Naturals with Comfort; Brueggman takes Vitaquest helm; and CBD Bath Soaks from allitom.

You may also be interested in...



Wellness New Product Roundup: 'The Truth' CBD, Hilo Performance Gummies, Syntech Offers More In US

Wakunaga expands Kyo-Dophilus probiotic line; Avadim Health's Theraworx reaches pharmacies; Naturade expands VeganSmart line; Goodbye UTI supplement contains d-mannose; Hilo Nutrition workout gummies alternative to powders, liquids; Syntech Nutrition adds to US distribution; and former NBA great Paul Pierce enters wellness business with cannabidiol oils, vaporizers.

Products Provider Nutrisystem Moves To Fitness Services Firm Tivity For $1.4Bn

Nutrisystem's sale to Tivity Health comes after a year of expanding its nutritional products and related services with daily vitamin packs, nutritional bars and shakes and genetic-based analysis for a personal action plan focused on eating behaviors, nutrition and metabolism. Tivity's move into providing products, though, didn’t go over well with investors.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Topics

Related Companies

UsernamePublicRestriction

Register

RS139937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel